Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/2026
• Auteurs : Nicolas BarbierPierre PlotonHadrien TuletGaëlle ViennoisHugo LeblancBenoit BurbanMaxime Réjou-MéchainPhilippe VerleyJames BallDenis FeurerGrégoire Vincent
• Organismes : Botanique et Modélisation de l'Architecture des Plantes et des Végétations Botanique et Modélisation de l'Architecture des Plantes et des Végétations Botanique et Modélisation de l'Architecture des Plantes et des Végétations Botanique et Modélisation de l'Architecture des Plantes et des Végétations Botanique et Modélisation de l'Architecture des Plantes et des Végétations Université de Yaoundé I Ecologie des forêts de Guyane Botanique et Modélisation de l'Architecture des Plantes et des Végétations Botanique et Modélisation de l'Architecture des Plantes et des Végétations Botanique et Modélisation de l'Architecture des Plantes et des Végétations Laboratoire d'étude des Interactions Sol - Agrosystème - Hydrosystème Botanique et Modélisation de l'Architecture des Plantes et des Végétations
• Publié dans ISPRS Open Journal of Photogrammetry and Remote Sensing le 08/04/2024

---

Résumé : This study benefited from an "Investissement d'Avenir" grant managed by the Agence Nationale de la Recherche (CEBA, ref. ANR-10-LABX-25-01), via project PHENOBS. We also acknowledge the support of the UE Biodiversa+ BiodivMon program (Project Coforfunc). We are thankful to Ilona Clocher, Jean-Louis Smock, Jean-Yves Goret, Florian Jeanne and Julien Engel for their help with drone data acquisition and/or processing. Access to the Paracou site and infrastructure (https://paracou.cirad.fr) was granted by CIRAD/Ecofog, and we thank Géraldine Derroire and all Phenobs project participants. We are grateful to Raphaël Pélissier for helping in the initial shaping of the Phenobs project and for his continued support.

---

Fichiers liés : 2025.06.27.661894.full_bioarXiv.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/2026
• Auteurs : M. Desnos-OllivierAlexandre AlanioMaud Gits-MuselliKarine Boukris-SitbonAgathe BerthoAude Sturny-LeclèreEmilie GuemasPhilippe PoirierChristine BonnalMarie-Elisabeth BougnouxSophie BrunTaieb ChouakiNicole Desbois-NogardElisabeth ChachatyFlorence PersatMarc PihetAndré PaugamFrançoise BotterelMagalie DemarLoïc FavennecOlivier LortholaryFlorent MorioFrédéric GabrielArnaud FekkarJean-Pierre GangneuxCaroline MahincValérie Letscher-BruLaurence MillonFrédéric DalleJulie BonhommeMuriel NicolasBoualem SendidMilène SassoLaure CourtellemontAnne-Laure RouxEstelle CateauJuliette GuitardEdith MazarsFanny Lanternier
• Organismes : Institut Pasteur [Paris] Institut Pasteur [Paris] Hopital Saint-Louis [AP-HP] Hôpital Robert Debré Infection, Anti-microbiens, Modélisation, Evolution Institut Pasteur [Paris] Institut Pasteur [Paris] Institut Pasteur [Paris] Centre National de la Recherche Scientifique CHU Clermont-Ferrand Université Blaise Pascal - Clermont-Ferrand 2 AP-HP - Hôpital Bichat - Claude Bernard [Paris] Hôpital Necker - Enfants Malades [AP-HP] Hôpital Avicenne [AP-HP] CHU Amiens-Picardie Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique] Département de biologie et pathologie médicales [Gustave Roussy] Hospices Civils de Lyon SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques Infections Respiratoires Fongiques Groupe d'Étude des Interactions Hôte-Pathogène Maternité Port-Royal [CHU Cochin] Université Paris-Est Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française] Hôpital Charles Nicolle [Rouen] Institut Pasteur [Paris] Hôpital Necker - Enfants Malades [AP-HP] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Bordeaux Centre d'Immunologie et des Maladies Infectieuses Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Hôpitaux Universitaires de Strasbourg Centre Hospitalier Régional Universitaire de Besançon Laboratoire Chrono-environnement (UMR 6249) Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Hôpital Côte de Nacre [CHU Caen] CHU Pointe-à-Pitre / Abymes [Guadeloupe] Centre Hospitalier Régional Universitaire [CHU Lille] Centre Hospitalier Universitaire de Nîmes Université de Montpellier Centre Hospitalier Universitaire d'Orléans Assistance publique - Hôpitaux de Paris (AP-HP) Centre hospitalier universitaire de Poitiers = Poitiers University Hospital CHU Saint-Antoine [AP-HP] Centre Hospitalier de Valenciennes Institut Pasteur [Paris] Hôpital Necker - Enfants Malades [AP-HP]
• Publié dans Emerging Infectious Diseases le 27/10/2020

---

Résumé : Fungi in the family Trichosporonaceae are rarely involved in invasive disease but are frequently associated with colonization or respiratory allergic infection. Trichosporonaceae exhibit intrinsic resistance to echinocandin antimicrobial drugs, posing challenges for treatment and contributing to high mortality rates. We complied a nationwide analysis of 112 cases of invasive disease caused by Trichosporon spp. and related fungi, diagnosed in France over 20 years, that combined clinical data, susceptibility profiles, and molecular identification. We identified 12 species; T. asahii was the most common species recovered, and the new species T. austroamericanum was next. Comparison of clinical data highlighted species and genotypic differences, such as a much higher proportion of children infected by T. asahii and major differences in antimicrobial drug susceptibility. Correct identification is not only of epidemiologic interest but also necessary for patient management because of the varying clinical and microbiological characteristics found in different species.

---

Fichiers liés : 25-0504-combined.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/2026
• Auteurs : Thibaut DevilleSelim CheaibiM. LlariWei WeiAnaïs GaroJean-Philippe LepretreP. J. ArnouxCatherine Masson
• Organismes : Laboratoire de Biomécanique Appliquée Laboratoire Mécanismes d'Accidents Laboratoire de Biomécanique Appliquée Laboratoire de Biomécanique Appliquée UTAC S.A.S, Autodrome Linas, Montlhéry, France UTAC S.A.S, Autodrome Linas, Montlhéry, France Laboratoire de Biomécanique Appliquée Laboratoire de Biomécanique Appliquée
• Publié dans Accident Analysis & Prevention le 24/10/2020

---

Résumé : Powered two-wheeler (PTW) riders are vulnerable road users. Wearable airbags may help to reduce thorax injuries which are the most frequent AIS3+ injury. Nevertheless, actual tests and standard lack accident representativeness. The aim of the study was to determine realistic trunk impact conditions for representative accidents. Three accidents scenarios have been found through a literature review and their main configurations have been numerically investigated via multibody modelling. The 912 performed simulations were used to explore body contacts with counterparts over time, velocities and body orientation at contact.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/2026
• Auteurs : Bénédicte LelièvreCharlotte GodonPierre LegrasJeremie RiouDavid TernantJean-Philippe Bouchara
• Organismes : SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques Infections Respiratoires Fongiques Département de Pharmacologie-Toxicologie [CHU Angers] SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques Micro et Nanomédecines Translationnelles Membrane Signalling and Inflammation in reperfusion Injuries Centre Hospitalier Régional Universitaire de Tours SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques Infections Respiratoires Fongiques
• Publié dans Biomedicine and Pharmacotherapy le 28/10/2020

---

Résumé : Background: Posaconazole, a broad spectrum antifungal, may be used in salvage therapy for cerebral infections caused by Scedosporium species. In this study, its pharmacokinetics was investigated in a rat model of scedosporiosis to evaluate the effect of the infection on cerebral diffusion. Methods: Posaconazole was administered to two groups of rats randomized according to the infection status. Drug levels in plasma, cerebrospinal fluid, and brain tissue were measured up to 168 h after administration, and data were analyzed using a non-compartmental approach. In addition, interleukins (IL) (IL-1β and IL-10) were quantified by ELISA, and cerebral expression of genes encoding some efflux pumps was assessed by reverse transcription-quantitative PCR. Results: Cerebral diffusion of posaconazole and, to a lesser extent, cerebrospinal fluid exposure were significantly affected by infection. A ten-fold increase in the area under the curve and a delayed time (Tmax) to reach the maximum concentration (Cmax) were observed in the brain, along with a time lag to reach Cmax and Tmax between plasma and the brain. Infection was associated with changes in plasma pharmacokinetics, particularly at late sampling times. Conclusions: These findings suggest increased permeability of the blood-brain-barrier, possibly related to changes in IL or gene expression levels in the brain. Infection and the resulting inflammation should therefore be considered for therapeutic drug monitoring, especially in cases of cerebral infection.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/2026
• Auteurs : Anne QuinquenelRémi LetestuMagali Le Garff-TavernierStéphane MorissetFabien SubtilThérèse AurranKamel LaribiFlorence CymbalistaVincent LévyLaurence SimonDamien Roos-WeilVéronique LeblondMarie-Sarah DilhuydyCécile TomowiakCaroline DartigeasRomain GuièzeOlivier TournilhacEmmanuelle FerrantSophie de GuibertPierre FeugierFatiha MerabetStéphane LeprêtrePhilippe CarassouJulie GayBénédicte HivertLuc-Matthieu ForneckerJehan DupuisLysiane MolinaBruno VillemagneGuillaume CartronBernard DrenouBeatrice MahéOmar BenbrahimXavier CahuChristelle PortoisLoïc YsebaertFlorence Nguyen-KhacAbdelmalek DahmaniClaire QuineyValérie RouilléAlain DelmerAnne-Sophie Michallet
• Organismes : Hôpital universitaire Robert Debré [Reims] Service d'hématologie biologique [Avicenne] CHU Pitié-Salpêtrière [AP-HP] Centre Léon Bérard [Lyon] Service de Biostatistiques [Lyon] Institut Paoli-Calmettes Centre Hospitalier Le Mans (CH Le Mans) Hôpital Avicenne [AP-HP] Hôpital Avicenne [AP-HP] Centre Hospitalier Sud Francilien - Centre Hospitalier d'Evry CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université Service des maladies du sang Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Centre Hospitalier Régional Universitaire de Tours Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre Hospitalier Régional Universitaire de Nancy Centre Hospitalier de Versailles André Mignot Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Centre hospitalier régional de Metz-Thionville Centre Hospitalier de la Côte Basque Groupement des Hôpitaux de l'Institut Catholique de Lille Institut de Cancérologie de Strasbourg Europe Centre Hospitalier Henri Mondor d'Aurillac CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon CHU Montpellier = Montpellier University Hospital Institut de Génétique Moléculaire de Montpellier Centre Hospitalier Emile Muller [Mulhouse] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Hôpital La Source [Orléans] Centre Hospitalier Régional d'Orléans Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Service Hématologie - IUCT-Oncopole [CHU Toulouse] CHU Pitié-Salpêtrière [AP-HP] Hôpital Avicenne [AP-HP] CHU Pitié-Salpêtrière [AP-HP] CHU Montpellier = Montpellier University Hospital Hôpital universitaire Robert Debré [Reims] Centre Léon Bérard [Lyon]
• Publié dans EClinicalMedicine le 01/11/2020

---

Résumé : Background: For chronic lymphocytic leukaemia (CLL) and intermediate risk factors (unmutated IGHV and/or 11q deletion and/or complex karyotype; no TP53 alteration), the best first-line treatment is unclear. We compared an MRD-guided, fixed-duration ibrutinib-venetoclax (IV) regimen to fludarabine-cyclophosphamide-rituximab (FCR) in this population. Methods: The ERADIC randomised, phase 2 trial (NCT04010968), conducted at 35 French hospitals, recruited previously untreated, fit adults with intermediate-risk CLL. Randomisation was 1:1 to: 6x4-weekly cycles of FCR (Months 1–6); or ibrutinib 420 mg/day from Month 1 plus venetoclax (ramp-up to 400 mg/day from Month 4) for a duration depending on the bone marrow measurable residual disease level at Month 9 (if undetectable at a threshold of <0·01% [BM uMRD4] to Month 15; otherwise to Month 27). Primary outcome was the BM uMRD4 rate at Month 27, by assessment oligocentrally (intent-to-treat, worst-case scenario method). Findings: Between 27 September 2019 and 31 January 2021, 120 patients were enrolled (73% male). At Month 27, the BM uMRD4 rate was 37% (22/59; 95% confidence interval [CI] 25, 51) with IV versus 13% (8/61; 95% CI 6, 24) with FCR. The high amount of missing BM MRD data, along with imbalance in missing data between arms, meant that no confirmatory statistics were performed. Best rate of BM uMRD4 plus peripheral blood uMRD5 was 47% (22/47) with IV versus 19% (8/43) with FCR (p = 0·0090). With median 43 months’ follow-up, progression-free survival was longer with IV versus FCR (estimated hazard ratio 0·35, 95% CI 0·16, 0·80, p = 0·012). By Month 27, six deaths had occurred (FCR: acute myeloid leukaemia, septic shock, myelodysplastic syndrome; IV: 2 sudden deaths, COVID-19). By the time of follow-up, the most common serious grade 3/4 events were infections and haematological toxicities with FCR, and infections and cardiovascular/metabolic toxicities with IV. Interpretation: Due to the high amount of missing BM MRD data at Month 27, the primary outcome statistical analysis was not deemed feasible. The outcomes reported are secondary and exploratory, and were not been powered for in the study design. A patient profile suitable for an MRD-guided, fixed-duration IV regimen requires consideration of potential toxicities. Funding: Abbvie and Janssen France.

---

Fichiers liés : 1-s2.0-S2589537025006418-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/2026
• Auteurs : Isabelle Sermet-GaudelusAlexia LetierceLaureline BertelootAnne-Sophie BonnelYuxin ChenPunit MakaniMairead Kelly-AubertFeriel KanounLucille PenalvaNesrine BouleghemTiphaine BihoueeStéphanie BuiHarriet CorvolVéronique HoudouinMarie MittaineAurelie TatopoulosLaurence WeissNathalie WizlaNathalie KapelAntoine BessouH TiddensDaan CaudriPhilippe ReixChristophe MarguetMarianne AlisonBaptiste ArnouatMelissande BaravalleMahassen BarbouraJeanne BarillonAudrey BarzicLilia BenhallaMyriam BenhamidaKhadidja BennourKatia BessaciAntoine BessouMarie BiardAurore BlondeBertrand BruneauAline Carsin-VuMathilde Casson-MasselinFrédérique ChedevergneCamille CisterneLaure CossonLaure CoudercCarole CouetteMarie-Laure DalphinPaola de CarliEric DeneuvilleGael DournesValerie DouzalHubert Ducou-Le-PointeClemence Dufour-BarbaRaphael EnaudMathilde FerryMorgane FlochPierre FoucaudFlaviu GaborAsma GabsiElsa GachelinCharlotte GiraudFatiha HassaniAudrey HerzogAntoine DelvalAnne HouzelFrédéric HuetAntoine HuttAhmed KhenicheMarie JaminKadiatou KabaSébastien KieferGuillaume LabbeAlice LadauradeJeanne LanguepinMuriel LauransLaurence Leclainche-VialaFaustine LefebvreThomas LefrancoisServane Lelez-SoquetMarion LenoirLouis-Marie LieberClotilde LivrozetCatthy LlerenaAlexia LetierceDamien MandrySarah MarchalChristophe MarguetSophie MayerStéphane MazurLaurent MelyRania MessaoudiBaptiste MorelCamille OhlmannJocelyne PengamStéphanie PerrezCaroline PerissonThomas PerrinIsabelle PetitPhilippe PetitJuliette PezronCarole Piccini-BaillyDelphine PouradierCinthia RamesAdelaide RegaPhilippe ReixMartine RemyNatacha RemusMarine RevillionLéa RoditisAnna RonayetteFlavie SadoneDjouher SahkiFloriane SauvageManuela ScalbertConsuelo SebastiasanchoIsabelle Sermet-GaudelusChiara SieloSophie SimonAnaëlle SimonneauFlorence SocchiNathalie StremlerAurélie TatopoulosMatthieu ThimmeschDiane Thomassonabdel-LatifGuillaume ThouveninCaroline ThumerelleCélia ThilliardJean-Yves TraversFrançoise TroussierSophie ValloisSaskia VandeperreJulie VialPhilippe VigneronMarie-Christine Werck-Gallois
• Organismes : Sorbonne Université Mucoviscidose: physiopathologie et phénogénomique [CRSA] CHU Trousseau [APHP] Centre de Recherche Saint-Antoine Hospices Civils de Lyon Hôpital Femme Mère Enfant [CHU - HCL] Centre National de la Recherche Scientifique Université Claude Bernard Lyon 1
• Publié dans The Lancet Respiratory Medicine le 23/10/2020

---

Résumé : ABSTRACT Background ATP‐binding cassette transporter A3 (ABCA3) deficiency is one of the most severe causes of childhood interstitial lung diseases (chILD). This study aims to report the RespiRare ABCA3 cohort and to establish phenotype‐genotype correlations. Methods Phenotypic and genotypic data of patients under 18 years were retrospectively included (1995–2023) in the RespiRare centers. The initial presentation and evolution of the subjects was analyzed depending on their genotype. Results The ABCA3 cohort comprised 36 children (30 families), including 5.5%, 22%, and 72% of null/null (no protein), null/other (potential residual function) and other/other genotypes respectively. A neonatal respiratory distress syndrome was observed in 31 (86%) subjects and 27 (75%) died at a median age of 3 months. The 5‐year overall survival was 25% with an overall median survival of 0.33 year (IQR 0.09–4.43). A neonatal onset ( p = 0.009) and the presence of pulmonary hypertension ( p = 0.037) impaired the prognosis. At the last follow‐up, the survival rates were 0/2 (0%), 4/8 (50%) and 6/26 (23%) in the null/null, null/other and other/other groups respectively. Eight of the 12 subjects who survived beyond 1 year carried at least one missense variant outside the nucleotide‐binding domains (NBD) ( n = 9) or the hypomorphic p.(Glu292Val) variant ( n = 1). Conclusion The variable presentation and outcome of chILD due to ABCA3 pathogenic variants are linked to the underlying genotype. Neonatal onset, null variants, and variants involving the NBD are of peculiar severity.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/2026
• Auteurs : Eric VandermolenPhilippe FerrandisFrédéric AllibertEmmanuel AugendreMassinissa NabetMartin RackJean-Pierre RaskinM. Cassé
• Organismes : Commissariat à l'énergie atomique et aux énergies alternatives - Laboratoire d'Electronique et de Technologie de l'Information SOITEC Semi-conducteurs à large bande interdite SOITEC Département Composants Silicium Institute of Information and Communication Technologies, Electronics and Applied Mathematics Institute of Information and Communication Technologies, Electronics and Applied Mathematics Institute of Information and Communication Technologies, Electronics and Applied Mathematics Commissariat à l'énergie atomique et aux énergies alternatives - Laboratoire d'Electronique et de Technologie de l'Information
• Publié dans Solid-State Electronics le 22/10/2020

---

Résumé : In this work, radio-frequency and traps properties of unintentionally doped polycrystalline silicon (polySi) deposited by low pressure chemical vapor deposition (LPCVD) on high resistivity silicon (HR-Si) substrate are characterized. Both volume (i.e. inside polySi) and interface traps (i.e. near polySi/HR-Si) are detected by photo-induced current transient spectroscopy (PICTS). A thermal budget of 900 ◦C during 2 h is sufficient to observe trap densities reduction near the polySi/HR-Si interface, affecting the RF performance of the fabricated substrates.

---

Fichiers liés : Traps-and-RF-Characterization-of-Polysilicon-Layer_draft_no-T1100_final.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/2026
• Auteurs : Margherita FabbriAymeric LanoreNathalie BertilleJean-Christophe CorvolOlivier J. RascolPhilippe RémyLuc DefebvreChloé LaurencinJean-Philippe AzulaySolène FrismandPhilppe DamierCaroline Giordana ReutherFazia Mélissa TirClaire ThiriezGwendoline DupontJean-Luc HouetoChristian GenyGiovanni CastelnovoAnne Doe de MaindrevilleSophie DrapierDavid MaltêteSolène AnsquerMatthieu AnheimFlorence TubachChristine Brefel-Courbon
• Organismes : Centre d'investigation clinique de Toulouse Toulouse NeuroImaging Center Institut du Cerveau = Paris Brain Institute Centre de pharmacoépidémiologie AP-HP Centre de pharmacoépidémiologie AP-HP Centre d'investigation clinique de Toulouse Centre d’Excellence en Maladies Neurodégénératives IMRB - "NeuroPsychologie Interventionnelle" [Créteil] Lille Neurosciences & Cognition - U 1172 Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM] Service de neurologie [CHRU Nancy] Centre d'investigation clinique (CIC) de Nantes -CIC Plurithématique Service de Neurologie [CHU Nice] CIC de Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402) Service de neurologie [CHU de Poitiers] Service de Neurologie [Strasbourg] Service de neurochirurgie [CHU Dijon] Epidémiologie des Maladies Chroniques en zone tropicale Service de Neurologie [CHU Limoges] CHU Montpellier = Montpellier University Hospital Service de Neurologie [CHU Nimes] Service de neurologie [Reims] Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Service de neurologie [Rouen] CIC de Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402) Service de Neurologie [Strasbourg] Institut Pierre Louis d'Epidémiologie et de Santé Publique Pharmacoépidémiologie et évaluation des soins [iPLesp] Centre de pharmacoépidémiologie AP-HP Toulouse NeuroImaging Center Centre d'investigation clinique de Toulouse
• Publié dans Parkinsonism & Related Disorders le 02/11/2020

---

Résumé : Background: Postural abnormalities (PA) and motor complications (MCs, including motor fluctuations - MFs- and levodopa-induced dyskinesia - LIDs) are hallmark of Parkinson's disease (PD) progression, yet their relationship remains poorly understood. Objective: To investigate the association between PA and MCs, motor symptoms, and non-motor symptoms (NMS) in patients with PD, and to assess whether PA influences the development of MCs over time. Methods: Data of the prospective NS-Park cohort (27 French PD Expert Centers) were analysed. PA was defined by a score ≥2 on item 3.13 of the MDS-UPDRS-III. Associations between PA and MCs, as well as with other motor symptoms and NMS, were assessed using logistic regression models. We used interval censoring survival models to assess the associations between PA at inclusion and the incidence of MCs. Analyses were adjusted for sex, age, disease duration, dopaminergic dose, and disease severity. Results: Among 13,037 included PD patients (58.7 % male, median age at diagnosis 61 years), 724 (5.6 %) presented with PA. Patients with PA had longer disease duration, higher disease severity, and higher dopaminergic treatment. PA exhibited a higher prevalence of troublesome MFs (OR: 5.96; 95 % CI: 4.25-8.32) and LIDs (OR: 2.81; 95 % CI: 1.79-4.30), while associations with milder MCs were inconsistent. However, PA was not significantly associated with the development of MCs during follow-up. Conclusions: PA are associated with more frequent severe MCs, and a higher burden of motor and NMS, making patient care particularly challenging.

---

Fichiers liés : Fabbri et al. - 2025 - Motor complications and postural abnormalities interplay in Parkinson’s disease_removed.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/2026
• Auteurs : Antoine GavoilleMikaïl NourredineFabien RollotRomain CaseyGuillaume MatheyAnne KerbratJonathan CironJérôme de SèzeBruno StankoffÉlisabeth MaillartAurélie RuetPierre M. LabaugeArnaud KwiatkowskiHélène ZéphirCaroline PapeixGilles-Louis DeferChristine Lebrun-FrenayThibault MoreauDavid-Axel LaplaudEric BergerPierre ClavelouEric ThouvenotOlivier HeinzlefJean PelletierAbdullatif Al KhedrOlivier CasezBertrand BourreAbir WahabLaurent MagySolène MoulinJean-Philippe CamdessanchéInès DoghriMariana SarovKarolina HankiewiczCorinne PottierAmélie dos SantosÉric ManchonMaia TchikviladzeMuriel RabilloudFabien SubtilSandra Vukusic
• Organismes : Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Service de Biostatistiques [Lyon] Hospices Civils de Lyon Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Service de Biostatistiques [Lyon] Observatoire Français de la Sclérose En Plaques [Lyon] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Fondation Eugène Devic EDMUS Hospices Civils de Lyon Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Observatoire Français de la Sclérose En Plaques [Lyon] Fondation Eugène Devic EDMUS Hospices Civils de Lyon Service de neurologie [CHRU Nancy] INterdisciplinarité en Santé Publique Interventions et Instruments de mesure complexes Centre d'investigation clinique de Nancy Service de neurologie [Rennes] Neuroimagerie: méthodes et applications Institut Toulousain des Maladies Infectieuses et Inflammatoires Centre Ressources et Compétences sclérose en plaques (CRC-SEP) [CHU Toulouse] CIC Strasbourg Service de Neurologie [Strasbourg] Institut du Cerveau = Paris Brain Institute CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] Service de neurologie [Bordeaux] Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale Centre Hospitalier Régional Universitaire [Montpellier] Université de Montpellier Hôpital Saint Vincent de Paul [Lille] Lille Neurosciences & Cognition - U 1172 Centre Hospitalier Régional Universitaire [CHU Lille] Centre de Ressources et de Compétences sur la Sclérose en Plaques (CRC-SEP) [Lille] Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Université Paris Cité Service de Neurologie [CHU Caen] Normandie Université UR2CA - URRIS - Unité de Recherche sur le syndrome Radiologique ISolé et maladies apparentées Service de Neurologie [CHU Nice] Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon) Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre d'investigation clinique (CIC) de Nantes -CIC Plurithématique Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Service de Neurologie [CHRU Besançon] Service Neurologie [CHU Clermont-Ferrand] Neuro-Dol Service de Neurologie [CHU Nimes] Institut de Génomique Fonctionnelle Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy] Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM] Service de neurologie [Amiens] Pôle Psychiatrie et Neurologie [Grenoble] Translational Research in Autoimmunity and Inflammation Group Service de neurologie [Rouen] Hôpital Henri Mondor Service de Neurologie [CHU Limoges] Service de neurologie [Reims] Service de Neurologie [CHU de Saint-Étienne] Centre Hospitalier Régional Universitaire de Tours Service de neurologie [Le Kremlin Bicêtre] Centre Hospitalier de Saint-Denis [Ile-de-France] Hôpital NOVO Service de neurologie [CHU de Poitiers] CIC de Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402) Centre Hospitalier de Gonesse Hôpital Foch [Suresnes] Alte University [Tbilissi] Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Service de Biostatistiques [Lyon] Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Service de Biostatistiques [Lyon] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Observatoire Français de la Sclérose En Plaques [Lyon] Hospices Civils de Lyon Fondation Eugène Devic EDMUS
• Publié dans Journal of Neurology, Neurosurgery and Psychiatry le 25/10/2020

---

Résumé : Background: Target trial emulation (TTE) offers a formal framework for causal inference using observational data, but its validity must be evaluated in each research domain by replicating randomised clinical trials (RCTs). We aimed to replicate eight RCTs evaluating the efficacy of disease-modifying therapies (DMTs) in multiple sclerosis (MS) using French registry data. Methods: This multicentre, retrospective, observational study was conducted using data extracted in December 2023 from the Observatoire Français de la Sclérose en Plaques (OFSEP) database. For each emulated trial, patients were included when they initiated one of the DMT evaluated in the corresponding RCT and met its inclusion criteria. Clinical outcomes were the annualised relapse rate and 3-month confirmed Expanded Disability Status Scale progression. Radiological outcomes were new/enlarged T2-lesions and new gadolinium-enhanced T1-lesions on a brain MRI. A targeted maximum likelihood estimator was used to estimate the treatment effect adjusted for confounding factors between groups and corrected for censoring and missing outcome assessment. Results: 14 111 patients were included in eight emulated trials: ASSESS (fingolimod vs glatiramer acetate), BEYOND (interferon beta vs glatiramer acetate), CONFIRM (dimethyl fumarate (DMF) vs glatiramer acetate), OPERA (ocrelizumab vs interferon beta), REGARD (interferon beta vs glatiramer acetate), RIFUND-MS (rituximab vs DMF), TENERE (teriflunomide vs interferon beta) and TRANSFORMS (fingolimod vs interferon beta). Treatment effects estimated in emulated trials were concordant with RCT findings in seven of eight trials for relapse rate, and in all six trials assessing disability progression. Radiological outcomes were more challenging to replicate; concordance was achieved in three of five trials for new T2-lesions, and one of four trials for new gadolinium-enhanced T1-lesions. Conclusion: The combined use of a TTE methodology and high-quality registry data is a valid tool to evaluate treatment effectiveness in MS.

---

Fichiers liés : Gavoille et al 2025.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/2026
• Auteurs : Olivier GrimaudEmmanuelle LeraySahar BayatChristophe FermanianSylvie MartinMyriam MaumyJean-Marc PhilippeEric MauryAgnès Ricard-HibonPierre TattevinMarc NoizetFrançois BraunManuel DolzMarc-Antoine SanchezHélène Coignard-BiehlerNathalie PrietoHugues DelamareVirginie CayréPierre CarliAlbert VuagnatJulien PottecherAsaël BergerLaure Abensur VuillaumeGuillaume LouisHélène BeringuerSebastien GetteThierry CapsKhaldoun KuteifanChristian FuchsLionel NaceBruno MourvillierStéphane GennaiSonia FoalemClaudia CiurelCosimo BriganteLionel PopoffFarid ArezkiAnne WeissFerhat MezianiFrancis SchneiderPaul-Michel MertesPascal LexaBetty FleuryElisabeth GaertnerGaëtan PlantefeveHenri FaureGuillaume Gelé DecaudinYves CohenFréderic AdnetElie ZogheibCharles DamoiselMathieu BoutonnetEmmanuel WeissJean-Damien RicardGeorges-Antoine CapitaniMarie BaronFrédérique SchortgenArmand Mekontso DessapEric LecarpentierEvelina OchinArmelle SeverinThomas LoebNicholas HemingPierre MoineDjillali AnnaneFabrice BertrandPhilippe DurandLucille WildenbergAnatole HarroisJean-Louis TeboulMartial ThyraultSabrine NakaaSophie Guilmin-CreponStéphane DaugerMarie BorelMatthieu LangloisAnne-Charlotte GianinazziFranck VerdonkBruno MégarbaneMuriel FartoukhLionel LamhautCédric BruelEmmanuel GuérotAlexy Tran DinhNathalie ZappellaTiphaine GirardPhilippe MontraversJean-Louis DubostMarie GrangeonGaël PitonSébastien Pili-FlouryThibault DesmettreToufiq El CadiBérengère VivetMarie ClavierDavid CoregeJean-François CicalaPaul-Simon PugliesiJean-Paul DenisEléonore TimsitSébastien MirekMohamed DyaniRené-Gilles PatrigeonBernard LecomteLaura FedericiLaurent SerpinPierre CalligeClément DubostOlivier RichardVirginie LaurentPhilippe IchaiJulio BadieMorlaye SanoBenoît PlaudMichael DarmonElie AzoulayDaniel da SilvaMourad LakhdariAlexandre BoyerDavid Tran VanCamille FoucaultThierry MayetQuentin LevratCédric DarreauPierre-Yves CordierRaphaël ParisMarie SouryMaxime GarnierPatrick LafforgueRomaric GrenotArnaud ThillePierre KergoatPhilippe GoutorbeFanny Bounes-VardonAntoine GalyOlivier de SoyresTahar SaghiHubert GrandLaurent MullerHélène CharbonneauKevin QuesnelJérôme PillotFrançois-Michel BelonclePierre AsfarSigismond LasockiDavid SchnellAnne RenaultOlivier HuetClaude CohenMarion CostecaldeElodie BrunelPhilippe PetuaAudrey DestizonsCaroline PoupletAntoine RoquillyJean ReignierBertrand SouweineJean-Etienne BazinJennifer BrunetJean-Baptiste MichotAurélien SeemannFabienne TamionFrancis RemerandPierre-François DequinAdel MaamarYoann LauneyPierre-Thierry PiechaudAurélien FrerouGuillaume SchnellPierre FillâtreChloé ThillGuillaume GrilletPierre-Yves EgreteauJohann AuchabiePierre-Louis DeclercqBenoît RozeMarc-Olivier FischerLoïc DopeuxRamin RavanLuc JarrigeChristophe FaisyBertrand SauneufNicolas PichonFabrice PrevostAgathe DelboveMaud JonasSandrine Bedon CarteGaël PradelAntoine Vieillard-BaronSalah BoussenMarc GainnierSamuel LehingueMarie-Christine HeraultMichel DurandPhilippe DeswardtPhilippe CamarasaCarole IchaiJean-Emmanuel AlphonsineBruno MarquerVincent WillemsAlexandre RobertPierre-Marie BertrandNadiejda AntierToufic FingeLucie MoutonTouraj RastegarTobias GrafJean ReuterClaude BraunStephan WatremezUwe SpetzgerAndré MichelMarc Bodenstein
• Organismes : Département Méthodes quantitatives en santé publique École des Hautes Études en Santé Publique Arènes: politique, santé publique, environnement, médias Recherche sur les services et le management en santé Centre d'Investigation Clinique [Rennes] Département Méthodes quantitatives en santé publique École des Hautes Études en Santé Publique Arènes: politique, santé publique, environnement, médias Recherche sur les services et le management en santé Arènes: politique, santé publique, environnement, médias École des Hautes Études en Santé Publique Département Méthodes quantitatives en santé publique Recherche sur les services et le management en santé Arènes: politique, santé publique, environnement, médias École des Hautes Études en Santé Publique Département Méthodes quantitatives en santé publique Recherche sur les services et le management en santé Arènes: politique, santé publique, environnement, médias École des Hautes Études en Santé Publique Département Méthodes quantitatives en santé publique Recherche sur les services et le management en santé Arènes: politique, santé publique, environnement, médias École des Hautes Études en Santé Publique Département Méthodes quantitatives en santé publique Recherche sur les services et le management en santé Ministère des Affaires sociales et de la Santé Direction Générale de la Santé Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie Département Urgences SAMU-SMUR 95, CHG Pontoise-Beaumont/Oise, Pontoise, France Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] ARN bactériens et médecine Groupe hospitalier de la région de Mulhouse et Sud-Alsace Centre hospitalier régional de Metz-Thionville Direction centrale du service de santé des armées Direction des Systèmes d’Information et du Numérique (DSIN), Service de Santé des Armées Françaises, Saint-Mandé-, France Service de Santé des Armées Service médical d’urgence, CHU de Lyon Hôpital Edouard Herriot [CHU - HCL] Santé publique France Antilles Agence Régionale de Santé Grand-Est SAMU 75 [Paris] Hôpital Necker - Enfants Malades [AP-HP] Drees, Ministère des affaires sociales et de la santé Hôpitaux Universitaires de Strasbourg TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group TRANSCOV-study group
• Publié dans Chest le 29/10/2020

---

Résumé : Background: In a context of overwhelming demand, mass transfers between intensive care units (ICU) were organized in France during the first COVID-19 epidemic wave (spring 2020). According to early reports, transferred patients experienced a 3-to-4-fold lower ICU case fatality. It is not known whether this difference stems only from the selection of healthier patients for transfer. Research question: Is the 28-day ICU case fatality of transferred patients different from that of matched control (not transferred) patients? Study design and methods: Multicenter retrospective cohort study that included 285 transferred patients, and 667 control (not transferred) patients admitted simultaneously (± 2 days) to the same "origin" ICU and alive five days after the transfer date. The 28-day ICU case fatality and clinical events during ICU stay were compared in transferred and control patients. Results: At ICU admission, age, COVID-19 severity, comorbidities and Simplified Acute Physiology Score II (SAPS II) were similar, but transferred patients were lighter (81 versus 89 kg, p<0.0001) and more autonomous than the matched control patients (64.5 versus 55.0%, p=0.01). Case fatality was approximately 7-fold lower in transferred patients (adjusted incidence rate ratio = 0.14 [95% CI: 0.10-0.19]). ICU stay was longer and delirium, psychiatric disorders and neuromuscular blockade exposure were more frequent in transferred patients than controls. Conversely, acute kidney injury was more frequent in controls (51.5 versus 37.7%, p<0.0001). Interpretation: Although the selection of healthier patients likely contributed to better survival, removal from an overcrowded care environment probably also explains the large survival benefit associated with transfer. By reducing workload, mass transfers might have also benefited patients who remained in origin ICUs. Organizing mass transfers as early as possible may be an appropriate strategy for mitigating the impact of an overwhelming intensive care demand.

---

Fichiers liés : Grimaud - 2025 - Mass medical evacuations to decrease the intensive care burden _Article_Transcov_CHEST2025.pdf

---

Source